2024
DOI: 10.1002/advs.202307940
|View full text |Cite
|
Sign up to set email alerts
|

In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy

Zhangyi Luo,
Zhuoya Wan,
Pengfei Ren
et al.

Abstract: PARP inhibitors (PARPi)‐based synthetic lethal therapy demonstrates limited efficacy for most cancer types that are homologous recombination (HR) proficient. To potentiate the PARPi application, a nanocarrier based on 5‐azacytidine (AZA)‐conjugated polymer (PAZA) for the codelivery of AZA and a PARP inhibitor, BMN673 (BMN) is developed. AZA conjugation significantly decreased the nanoparticle (NP) size and increased BMN loading. Molecular dynamics simulation and experimental validations shed mechanistic insigh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 64 publications
0
1
0
Order By: Relevance
“…These nanoparticles are particularly beneficial in targeting cancer cells while minimizing damage to healthy tissues (144)(145)(146)(147). This selective targeting reduces potential side effects and toxicity, thereby improving both the bioavailability and antitumor efficacy (148,149). One of the key advantages of nanoparticle-based drug delivery is the ability to engineer systems that release multiple drugs simultaneously into tumors, at a controlled rate or in response to specific triggers like pH, glutathione or reactive oxygen species (150).…”
Section: Nanotechnology-based Therapy Through Targeting Serpinb9mentioning
confidence: 99%
“…These nanoparticles are particularly beneficial in targeting cancer cells while minimizing damage to healthy tissues (144)(145)(146)(147). This selective targeting reduces potential side effects and toxicity, thereby improving both the bioavailability and antitumor efficacy (148,149). One of the key advantages of nanoparticle-based drug delivery is the ability to engineer systems that release multiple drugs simultaneously into tumors, at a controlled rate or in response to specific triggers like pH, glutathione or reactive oxygen species (150).…”
Section: Nanotechnology-based Therapy Through Targeting Serpinb9mentioning
confidence: 99%